9Z,12Z,15Z,18Z,21Z-tetracosapentaenoic acid | 68378-48-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 9Z,12Z,15Z,18Z,21Z-tetracosapentaenoic acid
• 英文别名: (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoic acid
• CAS: 68378-48-3
• 化学式: C₂₄H₃₈O₂
• 分子量: 358.6
• InChiKey: NPTIBOCVSPURCS-JLNKQSITSA-N

物化性质

• 溶解度：
  乙醇：0.5mg/mL；乙醇:PBS(pH 7.2) (1:1): 0.5 mg/mL
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  26
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] PROCESS FOR INCREASING THE STABILITY OF A COMPOSITION COMPRISING POLYUNSATURATED OMEGA-6 FATTY ACIDS<br/>[FR] PROCÉDÉ D'AUGMENTATION DE LA STABILITÉ D'UNE COMPOSITION COMPRENANT DES ACIDES GRAS OMÉGA-6 POLYINSATURÉS
  申请人：EVONIK DEGUSSA GMBH

  公开号：WO2016102316A1

  公开（公告）日：2016-06-30

  The present invention relates to processes for increasing the stability of compositions comprising polyunsaturated omega-6 fatty acids against oxidation. The processes comprise the following steps: (i) providing a starting composition comprising at least one polyunsaturated omega-6 fatty acid component; (ii) providing a lysine composition; (iii) admixing aqueous, aqueous-alcoholic or alcoholic solutions of starting composition and lysine composition, and subjecting resulting admixture to spray drying conditions subsequently, thus forming a solid product composition comprising at least one salt of a cation derived from lysine with an anion derived from a polyunsaturated omega-6 fatty acid; the product composition exhibiting a solvent content SC selected from the following: SC < 5 wt%, SC < 3 wt%, SC < 1 wt%, SC < 0.5 wt%. Compositions obtainable by such spray drying processes and use of such compositions for the manufacture of food, nutritional and pharmaceutical products are further comprised by the present invention.

  本发明涉及增加含有多不饱和ω-6脂肪酸的组合物抗氧化稳定性的过程。该过程包括以下步骤：(i)提供包含至少一种多不饱和ω-6脂肪酸成分的起始组合物；(ii)提供赖氨酸组合物；(iii)混合起始组合物和赖氨酸组合物的水、水醇或醇溶液，并随后将所得混合物暴露于喷雾干燥条件，从而形成包含至少一种来自赖氨酸阳离子和来自多不饱和ω-6脂肪酸阴离子的盐的固体产品组合物；所述产品组合物具有以下所选的溶剂含量SC：SC < 5 wt%，SC < 3 wt%，SC < 1 wt%，SC < 0.5 wt%。通过这种喷雾干燥过程获得的组合物以及利用这种组合物制造食品、营养和制药产品的方法也包含在本发明中。
• AMINO ACID SALTS OF UNSATURATED FATTY ACIDS
  申请人：Thetis Pharmaceuticals LLC

  公开号：US20170119841A1

  公开（公告）日：2017-05-04

  The present invention provides compounds of Formula I and Formula II and related compositions and methods.

  本发明提供了Formula I和Formula II的化合物以及相关的组合物和方法。
• [EN] IODINATED PRODUCTS INTENDED FOR A USE FOR THE MEDICAL IMAGING AND THEIR METHODS OF PREPARATION<br/>[FR] PRODUITS IODÉS DESTINÉS À ÊTRE UTILISÉS POUR L'IMAGERIE MÉDICALE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：UNIV STRASBOURG

  公开号：WO2013121284A1

  公开（公告）日：2013-08-22

  The present invention concerns an iodinated lipophilic compound of formula (I) or (II) : AG-R (I) or AG-X-R (II) wherein - AG represents an unsaturated or saturated (C8-C52) aliphatic hydrocarbon chain found in fatty acids having or not a double bond, an unsaturated or saturated aromatic cycle with an hydrocarbon chain, a sterol, an unsaturated or saturated (C8-C52) aliphatic hydrocarbon chain ended by an amino group having or not a double bound, - X represents a spacer such as a diacid, a diol (like aliphatic diol, polyethylene glycol comprising 1 to 50 ethylene glycol groups) or an amino acid, - R represents a benzene ring with one, two or three iodine atoms and a carboxylic group or an alcohol group.

  本发明涉及一种具有以下结构的碘化亲脂性化合物（I）或（II）：AG-R（I）或AG-X-R（II），其中- AG代表脂肪酸中的不饱和或饱和（C8-C52）脂肪烃链，具有或不具有双键，带有碳氢链的不饱和或饱和芳香环，甾醇，由氨基结束的不饱和或饱和（C8-C52）脂肪烃链，- X代表间隔物，如二酸，二醇（如脂肪二醇，聚乙二醇，包含1至50个乙二醇基团）或氨基酸，- R代表一个苯环，带有一个、两个或三个碘原子和一个羧基或羟基。
• [EN] PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF<br/>[FR] INHIBITEURS PEPTIDIQUES DE L'ACTIVITÉ DE KINASE D'ADHÉRENCE FOCALE ET UTILISATION ASSOCIÉES
  申请人：UNIV ARIZONA

  公开号：WO2021042064A1

  公开（公告）日：2021-03-04

  This disclosure provides peptides which have an affinity for the focal adhesion targeting (FAT) domain of focal adhesion kinase (FAK). In particular, the peptides are modified and derived from the sequence of the LD2 alpha helical domain of paxillin (e.g., LD2 peptides), the LD4 domain of paxillin (e.g., LD4 peptides), and CD8 peptides. These peptides are capable of blocking an interaction between paxillin and FAK, thereby inhibiting FAK activity related to FAK-paxillin interaction. The invention further provides uses for such peptides as therapeutics for the treatment of cancer and other diseases characterized with FAK activity and/or expression (e.g., fibrosis).

  本公开提供了对焦粘附激酶（FAK）的焦粘附靶向（FAT）结构域具有亲和力的肽。具体来说，这些肽经过修改并来源于paxillin的LD2α螺旋结构域序列（例如LD2肽）、paxillin的LD4结构域（例如LD4肽）和CD8肽。这些肽能够阻断paxillin与FAK之间的相互作用，从而抑制与FAK-paxillin相互作用相关的FAK活性。该发明进一步提供了这些肽作为治疗癌症和其他具有FAK活性和/或表达（例如纤维化）特征的疾病的治疗药物的用途。
• CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF
  申请人：MedWell Laboratories Ltd.

  公开号：US20160120995A1

  公开（公告）日：2016-05-05

  Novel chemical conjugates derived from unsaturated fatty acids and therapeutically active agents, are disclosed. The chemical conjugates are designed and characterized as COX-2 and/or 5-LOX inhibitors and are useful in the treatment of inflammatory diseases, dermatitis and disorders such as Alzheimer's disease, Parkinson's disease, asthma, osteoarthritis, rheumatoid arthritis, pain, primary dysmenorrhea, Crohn's disease and ulcerative colitis.

  本发明揭示了从不饱和脂肪酸和治疗活性剂衍生的新型化学共轭物。这些化学共轭物被设计和表征为COX-2和/或5-LOX抑制剂，并可用于治疗炎症性疾病、皮炎和阿尔茨海默病、帕金森病、哮喘、骨关节炎、类风湿性关节炎、疼痛、原发性痛经、克罗恩病和溃疡性结肠炎等疾病。